Skip to main content

Bioelectronics

See All Stories

We are living in the future: Alphabet & GSK in $715M deal to develop ‘bioelectronic medicine’

It doesn’t seem that long ago when putting tiny machines into people’s bodies to cure or manage diseases was the stuff of science-fiction, but bioelectronics is a real – if very new – field of medicine. Alphabet’s Verily Life Sciences (formerly Google Life Sciences) and pharma company GSK are teaming up to invest $715M in the tech over the next seven years.

Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices … 


Expand
Expanding
Close

Manage push notifications

notification icon
We would like to show you notifications for the latest news and updates.
notification icon
You are subscribed to notifications
notification icon
We would like to show you notifications for the latest news and updates.
notification icon
You are subscribed to notifications